Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 2:54 PM
Ignite Modification Date:
2025-12-25 @ 1:19 PM
NCT ID:
NCT03609359
Group ID:
EG000
Title:
Lenvatinib + Pembrolizumab
Description:
Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
Lenvatinib: Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
Pembrolizumab: Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, every 3 weeks (25 minutes to 40 minutes are acceptable).
Deaths Number Affected:
15
Deaths Number At Risk:
None
Serious Number Affected:
4
Serious Number At Risk:
29
Other Number Affected:
29
Other Number At Risk:
29
Study:
NCT03609359
Results Section:
NCT03609359
Adverse Events Module:
NCT03609359